OR WAIT null SECS
August 24, 2023
The patent grants Alterity 20 years of exclusivity over a new class of iron chaperone drug candidates.
August 18, 2023
The assessment aims to determine whether valproate use in men could lead to neurodevelopmental disorders in their children.
August 17, 2023
The indication for Pombiliti is a long-term enzyme replacement therapy (ERT) used in combination with miglustat for adults with late-onset Pompe disease (LOPD).
August 14, 2023
A report from the UK Bioindustry Association report indicated that biotech venture and public financing rose from £295 million in the first quarter to £382 million in the second quarter.
Cytomos will use the £4 million in funding to develop its dielectric spectroscopy technology.
August 02, 2023
Only a significant joint effort across the supply chain will help to make healthcare more sustainable and reduce the impact of climate change on global health.
July 27, 2023
Teva Pharmaceuticals and Alvotech will expand their partnership for the development and commercialization of biosimilar candidates.
Roche will pay up to $2.8 billion for the rights to Alnylam’s RNA-based hypertension therapeutic.
Janssen has received a positive opinion from the EMA for two novel bispecific antibodies, TALVEY (talquetamab) and TECVAYLI (teclistamab), which the company is developing to treat blood cancer.
July 24, 2023
The framework is now expanded beyond COVID-19 vaccines and treatments.